The first attempt in the use of TAT-GILZ was performed in a mouse model of DNBS-induced colitis, in which TAT-GILZ treatment successfully reduced the severity of spontaneously developed colitis in IL-10-knock-out mice. This evidence concerns the gene IL10 and colitis.